Next Article in Journal
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells
Next Article in Special Issue
A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State
Previous Article in Journal
Based on a Self-Feeder Layer, a Novel 3D Culture Model of Human ADSCs Facilitates Trans-Differentiation of the Spheroid Cells into Neural Progenitor-Like Cells Using siEID3 with a Laminin/Poly-d-lysine Matrix
Previous Article in Special Issue
Neuroimmune Regulation of Surgery-Associated Metastases
Review

Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy

1
Integrative Oncology Department, BC Cancer, Vancouver, BC V5Z 1L3, Canada
2
Immunophotonics Inc., St. Louis, MO 63110-1110, USA
3
Stephenson School of Biomedical Engineering, Gallogly College of Engineering, University of Oklahoma, Norman, OK 73019, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Fabrizio Mattei
Cells 2021, 10(3), 492; https://doi.org/10.3390/cells10030492
Received: 24 December 2020 / Revised: 14 February 2021 / Accepted: 19 February 2021 / Published: 25 February 2021
Ablation therapies have emerged as an effective tool for destroying cancerous tissue, but for advanced and disseminated tumors their application remains mainly a palliative measure. However, it is becoming increasingly clear that this limitation can be redressed by the use of intratumoral immune stimulating agents for amplifying potential antitumor immune responses that are induced by ablation therapies. A novel immune stimulating drug IP-001, a specific variant of the N-dihydrogalactochitosan (GC) family of molecules, has shown to be effective against metastatic tumors, when combined with different forms tumor ablation. It acts as a multi-function immune stimulant both by directly inhibiting cell membrane repair and recycling of ablation-damaged tumor cells, and indirectly by sequestering ablation-released tumor antigens, as well as recruiting and stimulating antigen presenting cells to induce a potent Th1 type T cell response against the cancer. In this review, we briefly discuss the current applications of local ablation for cancer treatment and the effects of GC in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO). View Full-Text
Keywords: N-dihydrogalactochitosan (GC); IP-001; tumor ablation; immunoadjuvant; immune stimulant; metastatic tumors; combination of ablation and immune stimulation; interventional immuno-oncology (IIO) N-dihydrogalactochitosan (GC); IP-001; tumor ablation; immunoadjuvant; immune stimulant; metastatic tumors; combination of ablation and immune stimulation; interventional immuno-oncology (IIO)
Show Figures

Graphical abstract

MDPI and ACS Style

Korbelik, M.; Hode, T.; Lam, S.S.K.; Chen, W.R. Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy. Cells 2021, 10, 492. https://doi.org/10.3390/cells10030492

AMA Style

Korbelik M, Hode T, Lam SSK, Chen WR. Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy. Cells. 2021; 10(3):492. https://doi.org/10.3390/cells10030492

Chicago/Turabian Style

Korbelik, Mladen, Tomas Hode, Samuel S.K. Lam, and Wei R. Chen. 2021. "Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy" Cells 10, no. 3: 492. https://doi.org/10.3390/cells10030492

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop